EP4344738A3 - Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation - Google Patents
Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation Download PDFInfo
- Publication number
- EP4344738A3 EP4344738A3 EP23215091.2A EP23215091A EP4344738A3 EP 4344738 A3 EP4344738 A3 EP 4344738A3 EP 23215091 A EP23215091 A EP 23215091A EP 4344738 A3 EP4344738 A3 EP 4344738A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- fusion proteins
- insulin
- long acting
- ultra
- acting insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 6
- 108020001507 fusion proteins Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 241000282465 Canis Species 0.000 abstract 2
- 241000282324 Felis Species 0.000 abstract 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862692507P | 2018-06-29 | 2018-06-29 | |
US201862692498P | 2018-06-29 | 2018-06-29 | |
US201862693814P | 2018-07-03 | 2018-07-03 | |
US201862696645P | 2018-07-11 | 2018-07-11 | |
US201862698648P | 2018-07-16 | 2018-07-16 | |
US201862702167P | 2018-07-23 | 2018-07-23 | |
US201862719347P | 2018-08-17 | 2018-08-17 | |
US201862740735P | 2018-10-03 | 2018-10-03 | |
US201862743358P | 2018-10-09 | 2018-10-09 | |
US201862774682P | 2018-12-03 | 2018-12-03 | |
US201862781378P | 2018-12-18 | 2018-12-18 | |
US201862781368P | 2018-12-18 | 2018-12-18 | |
US201962824176P | 2019-03-26 | 2019-03-26 | |
US201962827809P | 2019-04-01 | 2019-04-01 | |
US201962837188P | 2019-04-22 | 2019-04-22 | |
EP19826154.7A EP3655006B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
PCT/US2019/040010 WO2020006529A1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
EP21207279.7A EP4011908B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
EP22203969.5A EP4186920B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21207279.7A Division EP4011908B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
EP22203969.5A Division EP4186920B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
EP19826154.7A Division EP3655006B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4344738A2 EP4344738A2 (fr) | 2024-04-03 |
EP4344738A3 true EP4344738A3 (fr) | 2024-05-22 |
Family
ID=68985236
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21164434.9A Active EP3892628B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
EP23215091.2A Pending EP4344738A3 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
EP19826154.7A Active EP3655006B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
EP22203969.5A Active EP4186920B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
EP21207279.7A Active EP4011908B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21164434.9A Active EP3892628B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19826154.7A Active EP3655006B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
EP22203969.5A Active EP4186920B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
EP21207279.7A Active EP4011908B1 (fr) | 2018-06-29 | 2019-06-28 | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
Country Status (15)
Country | Link |
---|---|
US (8) | US10947292B2 (fr) |
EP (5) | EP3892628B1 (fr) |
JP (2) | JP7417277B2 (fr) |
KR (1) | KR20210029210A (fr) |
CN (1) | CN113038964A (fr) |
AU (1) | AU2019291945A1 (fr) |
BR (1) | BR112020026777A2 (fr) |
CA (1) | CA3104144A1 (fr) |
DK (4) | DK4186920T3 (fr) |
FI (2) | FI4011908T3 (fr) |
HR (4) | HRP20230991T1 (fr) |
HU (3) | HUE058005T2 (fr) |
LT (4) | LT3892628T (fr) |
SI (4) | SI3892628T1 (fr) |
WO (1) | WO2020006529A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3939605A1 (fr) | 2016-12-09 | 2022-01-19 | Akston Biosciences Corporation | Fusions d'insuline-fc et méthodes d'utilisation |
FI4011908T3 (fi) | 2018-06-29 | 2023-08-04 | Akston Biosciences Corp | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät |
US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
WO2021011827A1 (fr) * | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
CN114846025A (zh) | 2019-12-19 | 2022-08-02 | 阿卡斯通生物科学公司 | 超长效胰岛素-Fc融合蛋白及其使用方法 |
US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
US11213581B2 (en) | 2020-04-10 | 2022-01-04 | Akston Biosciences Corporation | Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use |
US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
CA3189527A1 (fr) * | 2020-07-24 | 2022-01-27 | Jiangsu Gensciences Inc. | Proteine de fusion insuline-fc et son application |
CA3202345A1 (fr) * | 2020-12-14 | 2022-06-23 | Eli Lilly And Company | Methodes de traitement du diabete |
EP4373861A2 (fr) | 2021-07-23 | 2024-05-29 | Akston Biosciences Corporation | Protéines de fusion insuline-fc et méthodes d'utilisation pour traiter le cancer |
WO2023064711A2 (fr) * | 2021-10-14 | 2023-04-20 | Akston Biosciences Corporation | Protéines de fusion insuline-fc à action ultra-longue et méthodes d'utilisation |
TW202339790A (zh) | 2021-11-15 | 2023-10-16 | 美商美國禮來大藥廠 | 可保存之調配物 |
WO2023174370A1 (fr) * | 2022-03-16 | 2023-09-21 | 北京拓界生物医药科技有限公司 | Analogue de l'insuline humaine, sa protéine de fusion et son utilisation médicale |
WO2023247640A1 (fr) * | 2022-06-23 | 2023-12-28 | Sanofi | Insulines à chaîne unique et leurs conjugués fc |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010117760A2 (fr) * | 2009-03-30 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Protéines hybrides comprenant des portions fc d'anticorps canins |
CN103509118A (zh) * | 2012-06-15 | 2014-01-15 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
WO2016044676A2 (fr) * | 2014-09-18 | 2016-03-24 | AskGene Pharma, Inc. | Nouveaux agonistes du récepteur de l'érythropoïétine de félins |
WO2016119023A1 (fr) * | 2015-01-29 | 2016-08-04 | Nexvet Australia Pty Ltd | Agents diagnostiques et thérapeutiques |
WO2016178905A1 (fr) * | 2015-05-07 | 2016-11-10 | Eli Lilly And Company | Protéines de fusion |
WO2018009921A1 (fr) * | 2016-07-08 | 2018-01-11 | AskGene Pharma, Inc. | Protéine de fusion comprenant de la leptine et procédés de production et d'utilisation associés |
WO2018073185A1 (fr) * | 2016-10-17 | 2018-04-26 | Vetoquinol Sa | Région constante modifiée d'un anticorps |
WO2018107117A1 (fr) * | 2016-12-09 | 2018-06-14 | Akston Biosciences Corporation | Fusions d'insuline-fc et méthodes d'utilisation |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030040601A1 (en) | 2001-06-08 | 2003-02-27 | Ivan Diers | Method for making insulin precursors and insulin analog precursors |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US20100143479A1 (en) | 2008-12-04 | 2010-06-10 | Oakwood Laboratories, Llc | Method of making sustained release microparticles |
WO2010107520A1 (fr) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Conjugués d'insulines non déposées solubles et leurs utilisations |
CN101891823B (zh) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
CA2805739A1 (fr) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Conjugues medicaments-ligands, leur synthese et intermediaires correspondants |
AU2011282988A1 (en) * | 2010-07-28 | 2013-01-31 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
AR087433A1 (es) | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
US20140302028A1 (en) | 2011-11-18 | 2014-10-09 | Merck Sharp & Dohme Corp. | Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding |
KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
EP2885543B1 (fr) * | 2012-08-17 | 2019-01-16 | Dresser-Rand Company | Système et procédé de détection de décrochage ou pompage dans des compresseurs radiaux |
WO2014093387A1 (fr) * | 2012-12-10 | 2014-06-19 | Kindred Biosciences, Inc. | Protéines hybrides du récepteur de vegf pour utilisation vétérinaire |
SG10201907106VA (en) | 2013-02-26 | 2019-09-27 | Hanmi Pharmaceutical Co Ltd | Novel insulin analog and use thereof |
CA2961037A1 (fr) * | 2014-10-06 | 2016-04-14 | Case Western Reserve University | Analogues de l'insuline a chaine unique biphasique |
CA2964918A1 (fr) * | 2014-10-20 | 2016-04-28 | Case Western Reserve University | Analogues d'insuline halogenes a activite biologique amelioree |
US10822386B2 (en) | 2014-12-24 | 2020-11-03 | Case Western Reserve University | Insulin analogues with enhanced stability and reduced mitogenicity |
KR20170106373A (ko) * | 2015-01-20 | 2017-09-20 | 케이스 웨스턴 리저브 유니버시티 | 선택적 신호전달 특성 및 감소된 유사분열촉진을 갖는 인슐린 유사체 |
KR20160101702A (ko) | 2015-02-17 | 2016-08-25 | 한미약품 주식회사 | 지속형 인슐린 또는 이의 아날로그 결합체 |
WO2016164937A2 (fr) * | 2015-04-10 | 2016-10-13 | Amgen Inc. | Mutéines de l'interleukine-2 pour l'expansion de lymphocytes t régulateurs |
AU2016257000B2 (en) * | 2015-05-04 | 2020-05-14 | Apogenix Ag | Single-chain CD40-receptor agonist proteins |
WO2016193380A1 (fr) | 2015-06-02 | 2016-12-08 | Novo Nordisk A/S | Insulines à extensions recombinées polaires |
CN108699120B (zh) | 2015-11-16 | 2022-05-13 | Ubi蛋白公司 | 用于延长蛋白质半衰期的方法 |
AU2017298565B2 (en) * | 2016-07-22 | 2021-08-19 | The Walter And Eliza Hall Institute Of Medical Research | Insulin analogs |
JP7158378B2 (ja) | 2016-09-23 | 2022-10-21 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリン受容体との結合力が減少された、インスリンアナログ及びその用途 |
AR111122A1 (es) | 2017-03-07 | 2019-06-05 | Univ Case Western Reserve | Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro |
US10572594B2 (en) | 2017-08-01 | 2020-02-25 | Intuit Inc. | Extracting domain-specific actions and entities in natural language commands recognized based on edition and recognition scores |
WO2019035010A1 (fr) | 2017-08-15 | 2019-02-21 | Kindred Biosciences, Inc. | Variants d'igg fc à usage vétérinaire |
AU2019255611A1 (en) | 2018-04-16 | 2020-11-12 | University Of Utah Research Foundation | Glucose-responsive insulin |
US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
FI4011908T3 (fi) | 2018-06-29 | 2023-08-04 | Akston Biosciences Corp | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät |
CA3114395A1 (fr) | 2018-09-25 | 2020-04-02 | Absci, Llc | Procedes de purification de proteines |
EP3861017A1 (fr) | 2018-10-05 | 2021-08-11 | Novo Nordisk A/S | Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a) |
JP2022507627A (ja) | 2018-11-19 | 2022-01-18 | ケース ウェスタン リザーブ ユニバーシティ | ポリ-アラニンc-ドメインのサブセグメントを有する単鎖インスリンアナログ |
AU2020279968A1 (en) | 2019-05-17 | 2021-12-16 | Case Western Reserve University | Variant single-chain insulin analogues |
WO2021011827A1 (fr) | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation |
JP2022542301A (ja) | 2019-07-31 | 2022-09-30 | イーライ リリー アンド カンパニー | リラキシン類似体およびその使用方法 |
CN114846025A (zh) | 2019-12-19 | 2022-08-02 | 阿卡斯通生物科学公司 | 超长效胰岛素-Fc融合蛋白及其使用方法 |
US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
-
2019
- 2019-06-28 FI FIEP21207279.7T patent/FI4011908T3/fi active
- 2019-06-28 WO PCT/US2019/040010 patent/WO2020006529A1/fr active Search and Examination
- 2019-06-28 CN CN201980056947.5A patent/CN113038964A/zh active Pending
- 2019-06-28 LT LTEP21164434.9T patent/LT3892628T/lt unknown
- 2019-06-28 CA CA3104144A patent/CA3104144A1/fr active Pending
- 2019-06-28 AU AU2019291945A patent/AU2019291945A1/en active Pending
- 2019-06-28 HU HUE19826154A patent/HUE058005T2/hu unknown
- 2019-06-28 EP EP21164434.9A patent/EP3892628B1/fr active Active
- 2019-06-28 EP EP23215091.2A patent/EP4344738A3/fr active Pending
- 2019-06-28 HU HUE21207279A patent/HUE062719T2/hu unknown
- 2019-06-28 JP JP2020573352A patent/JP7417277B2/ja active Active
- 2019-06-28 FI FIEP22203969.5T patent/FI4186920T3/fi active
- 2019-06-28 DK DK22203969.5T patent/DK4186920T3/da active
- 2019-06-28 EP EP19826154.7A patent/EP3655006B1/fr active Active
- 2019-06-28 HR HRP20230991TT patent/HRP20230991T1/hr unknown
- 2019-06-28 HU HUE21164434A patent/HUE060471T2/hu unknown
- 2019-06-28 SI SI201930392T patent/SI3892628T1/sl unknown
- 2019-06-28 HR HRP20220091TT patent/HRP20220091T1/hr unknown
- 2019-06-28 BR BR112020026777-5A patent/BR112020026777A2/pt unknown
- 2019-06-28 SI SI201930615T patent/SI4011908T1/sl unknown
- 2019-06-28 LT LTEPPCT/US2019/040010T patent/LT3655006T/lt unknown
- 2019-06-28 DK DK21207279.7T patent/DK4011908T3/da active
- 2019-06-28 EP EP22203969.5A patent/EP4186920B1/fr active Active
- 2019-06-28 EP EP21207279.7A patent/EP4011908B1/fr active Active
- 2019-06-28 HR HRP20221418TT patent/HRP20221418T1/hr unknown
- 2019-06-28 SI SI201930726T patent/SI4186920T1/sl unknown
- 2019-06-28 LT LTEP21207279.7T patent/LT4011908T/lt unknown
- 2019-06-28 DK DK19826154.7T patent/DK3655006T3/da active
- 2019-06-28 DK DK21164434.9T patent/DK3892628T3/da active
- 2019-06-28 HR HRP20240408TT patent/HRP20240408T1/hr unknown
- 2019-06-28 KR KR1020217002135A patent/KR20210029210A/ko unknown
- 2019-06-28 SI SI201930152T patent/SI3655006T1/sl unknown
- 2019-06-28 LT LTEP22203969.5T patent/LT4186920T/lt unknown
-
2020
- 2020-01-29 US US16/776,136 patent/US10947292B2/en active Active
- 2020-01-29 US US16/776,065 patent/US10870686B2/en active Active
- 2020-01-29 US US16/776,180 patent/US10851147B2/en active Active
- 2020-01-29 US US16/775,979 patent/US10961294B2/en active Active
- 2020-09-11 US US17/019,059 patent/US11261229B2/en active Active
-
2021
- 2021-09-29 US US17/488,852 patent/US11773151B2/en active Active
- 2021-09-29 US US17/488,685 patent/US11673934B2/en active Active
-
2023
- 2023-09-01 US US18/459,581 patent/US20240101635A1/en active Pending
- 2023-12-25 JP JP2023217822A patent/JP2024045117A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010117760A2 (fr) * | 2009-03-30 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Protéines hybrides comprenant des portions fc d'anticorps canins |
CN103509118A (zh) * | 2012-06-15 | 2014-01-15 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
WO2016044676A2 (fr) * | 2014-09-18 | 2016-03-24 | AskGene Pharma, Inc. | Nouveaux agonistes du récepteur de l'érythropoïétine de félins |
WO2016119023A1 (fr) * | 2015-01-29 | 2016-08-04 | Nexvet Australia Pty Ltd | Agents diagnostiques et thérapeutiques |
WO2016178905A1 (fr) * | 2015-05-07 | 2016-11-10 | Eli Lilly And Company | Protéines de fusion |
WO2018009921A1 (fr) * | 2016-07-08 | 2018-01-11 | AskGene Pharma, Inc. | Protéine de fusion comprenant de la leptine et procédés de production et d'utilisation associés |
WO2018073185A1 (fr) * | 2016-10-17 | 2018-04-26 | Vetoquinol Sa | Région constante modifiée d'un anticorps |
WO2018107117A1 (fr) * | 2016-12-09 | 2018-06-14 | Akston Biosciences Corporation | Fusions d'insuline-fc et méthodes d'utilisation |
Non-Patent Citations (2)
Title |
---|
STRIETZEL CATHERINE J ET AL: "In Vitrofunctional characterization of feline IgGs", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 158, no. 3, 5 February 2014 (2014-02-05), pages 214 - 223, XP028604528, ISSN: 0165-2427, DOI: 10.1016/J.VETIMM.2014.01.012 * |
TERADA T ET AL: "A chimeric human-cat Fc@c-Fel d1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1, the major cat allergen", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 120, no. 1, 13 February 2006 (2006-02-13), pages 45 - 56, XP024911178, ISSN: 1521-6616, [retrieved on 20060701], DOI: 10.1016/J.CLIM.2005.12.010 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4344738A3 (fr) | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation | |
EP4282473A3 (fr) | Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation | |
WO2015188132A8 (fr) | Procédés de construction de protéines de fusion d'immunoglobuline à terminaison amino et leurs compositions | |
WO2020077276A3 (fr) | Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci | |
WO2007070671A3 (fr) | Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4 | |
MX2019001925A (es) | Proteina de fusion del factor viii de la coagulacion sanguinea humana altamente glicosilada y metodo de fabricacion y aplicacion del mismo. | |
JP2018524358A5 (fr) | ||
JP2017527272A5 (fr) | ||
AR105616A1 (es) | Proteínas de fusión | |
EA200700391A1 (ru) | Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1 | |
MX2021010531A (es) | Proteina de fusion bifuncional y uso farmaceutico de la misma. | |
RU2017141727A (ru) | Одноцепочечные белки-агонисты рецептора cd40 | |
FI3452507T3 (fi) | Tau-immuunihoito | |
JP6711836B2 (ja) | 薬剤送達デバイス | |
JP2014525901A5 (fr) | ||
EP3711065A1 (fr) | Système et procédé pour prendre en charge l'utilisation d'un dispositif d'injection | |
WO2007022239A3 (fr) | Formulations pharmaceutiques utiles pour l'apport continu d'un medicament | |
ES2153367T3 (es) | Derivados de clorofila y de bacterioclorofila, su preparacion y composiciones farmaceuticas que los contienen. | |
PE20090311A1 (es) | Proteinas de fusion natriureticas | |
UY30324A1 (es) | Proteinas de fusion del rage, formulaciones y métodos de uso | |
WO2007107797A3 (fr) | Composition et procédé pour la médiation de réponse immunitaire | |
UA107180C2 (uk) | Туберкульозний білок rv1753c, композиція, що його містить, та застосування | |
EP4353250A3 (fr) | Methode de traitement ou d'amelioration de troubles metaboliques utilisant des proteines de liaison antagonistes pour des proteines de fusion agonistes du recepteur du peptide inhibiteur gastrique (gipr)/glp-1 | |
WO2020247388A3 (fr) | Composés de liaison de sous-unité de récepteur il-2alpha | |
CN108495671A (zh) | 药物注射装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3655006 Country of ref document: EP Kind code of ref document: P Ref document number: 4011908 Country of ref document: EP Kind code of ref document: P Ref document number: 4186920 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61P0003100000 Ipc: C07K0014620000 |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 3/10 20060101ALI20240412BHEP Ipc: C07K 7/08 20060101ALI20240412BHEP Ipc: A61K 38/00 20060101ALI20240412BHEP Ipc: C07K 14/62 20060101AFI20240412BHEP |